000 04006nam a22005895i 4500
001 978-981-97-3446-7
003 DE-He213
005 20251030112708.0
007 cr nn 008mamaa
008 240802s2024 si | s |||| 0|eng d
020 _a9789819734467
_9978-981-97-3446-7
024 7 _a10.1007/978-981-97-3446-7
_2doi
050 4 _aRC705-779
072 7 _aMJL
_2bicssc
072 7 _aMED079000
_2bisacsh
072 7 _aMJL
_2thema
100 1 _aGemma, Akihiko.
_eauthor.
_4aut
_4http://id.loc.gov/vocabulary/relators/aut
_981839
245 1 0 _aAnalysis File of Drug-Induced Lung Injury
_h[electronic resource] :
_bExpert Opinion for Analysis of Big Data /
_cby Akihiko Gemma.
250 _a1st ed. 2024.
264 1 _aSingapore :
_bSpringer Nature Singapore :
_bImprint: Springer,
_c2024.
300 _aXII, 116 p. 48 illus., 18 illus. in color.
_bonline resource.
336 _atext
_btxt
_2rdacontent
337 _acomputer
_bc
_2rdamedia
338 _aonline resource
_bcr
_2rdacarrier
347 _atext file
_bPDF
_2rda
505 0 _aPart I Understanding Drug-Induced Lung Injuries -- 1 Understanding Drug-Induced Lung Injuries -- Part 2 Actual Practice in Drug-Induced Lung Injuries of Each Drug -- 2 EGFR inhibitors (gefitinib, erlotinib, afatinib, osimertinib) -- 3 Anti-EGFR antibodies (cetuximab, panitumumab, necitumumab) -- 4 mTOR inhibitors (temsirolimus, everolimus) -- 5 Proteasome inhibitor (bortezomib) -- 6 Immune checkpoint inhibitors (nivolumab, pembrolizumab, atezolizumab, durvalumab) -- 7 Neoangiogenesis inhibitors (sunitinib, sorafenib, bevacizumab) -- 8 Other molecular targeted drugs (crizotinib, alectinib, etc.) -- 9 Antibody-drug conjugates (ADC) (trastuzumab emtansine, trastuzumab deruxtecan) -- 10 Anti-cancer drugs (TS-1, taxanes, CPT-11, platinum-containing drugs, etc.).
520 _aThis book describes the pathologic conditions of drug-induced lung injuries, monitoring strategies, and guides on how to interpret the evidence. It also dives into particular drugs that caused the disorder, such as EGFR inhibitors, anti-EGFR antibodies, mTOR inhibitors, proteasome inhibitors, immune checkpoint inhibitors, neoangiogenesis inhibitors, and other molecular targeted drugs. It outlines the analysis and interpretation of the post-marketing survey on surveillance of each drug for inducing pulmonary lesions presenting diffuse haziness. The data and analysis from this survey are valuable since a guideline is yet to be established due to limited clinical evidence and cases. As new drugs are developed, establishing treatment and event management is crucial. Thus, Drug-induced Pulmonary Disorder in Medical Oncology - Expert Opinion to Decipher Big Data summarizes the accumulated information to provide a foundation for further research advancement. The book offers a refreshing alternative to current approaches to medical oncology and respiratory diseases professionals and will also attract medical affairs members in global pharmaceutical companies.
650 0 _aRespiratory organs
_xDiseases.
_977494
650 0 _aMedical genetics.
_964976
650 0 _aDiseases
_xCauses and theories of causation.
_978871
650 0 _aOncology.
_970760
650 0 _aPharmacology.
_967844
650 0 _aGenetics
_xResearch.
_979924
650 1 4 _aPneumology.
_977495
650 2 4 _aClinical Genetics.
_973305
650 2 4 _aPathogenesis.
_978872
650 2 4 _aOncology.
_970760
650 2 4 _aPharmacology.
_967844
650 2 4 _aGenetics Research.
_979925
710 2 _aSpringerLink (Online service)
773 0 _tSpringer Nature eBook
776 0 8 _iPrinted edition:
_z9789819734450
776 0 8 _iPrinted edition:
_z9789819734474
776 0 8 _iPrinted edition:
_z9789819734481
856 4 0 _uhttps://doi.org/10.1007/978-981-97-3446-7
912 _aZDB-2-SME
912 _aZDB-2-SXM
999 _c62199
_d62199